AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said ...
Novel Aldosterone Synthase Inhibitor Lorundrostat Shows Promise for Uncontrolled Hypertension in CKD
A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.
India Today on MSN
Big hope for resistant hypertension patients
A novel experimental drug may soon change the outlook for patients battling hard-to-treat hypertension. AstraZeneca's ...
As of Monday, November 10, Mineralys Therapeutics, Inc.’s MLYS share price has surged by 8.40%, which has investors questioning if this is right time to sell.
Type 2 diabetes (T2D) incidence continues to rise among African Americans (AAs). However, it has been observed to plateau among non-Hispanic whites (NHWs). Moreover, T2D-associated mortality and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback